Forte Biosciences (FBRX) Operating Expenses (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Operating Expenses data on file, last reported at $22.4 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 39.17% year-over-year to $22.4 million in Q1 2026; TTM through Mar 2026 was $77.0 million, a 71.35% increase from a year earlier, with the FY2025 full-year figure at $70.7 million, up 93.04% from the prior year.
• Operating Expenses for Q1 2026 stood at $22.4 million, down from $24.6 million in the prior quarter.
• Over the last five years, Operating Expenses for FBRX reached as high as $24.6 million in Q4 2025 and fell as low as $2.5 million in Q1 2022.
• Historically, Operating Expenses has averaged $10.4 million across 5 years, with a median of $8.6 million in 2024.
• Across the five-year window, Operating Expenses slumped 55.54% in 2022 and jumped 234.25% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $4.9 million in 2022, then advanced by 29.2% to $6.4 million in 2023, then advanced by 15.2% to $7.4 million in 2024, then soared by 234.25% to $24.6 million in 2025, then decreased by 8.68% to $22.4 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $22.4 million in Q1 2026, $24.6 million in Q4 2025, and $18.4 million in Q3 2025.